N-acyl 6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist

…, S Egashira, Y Goto, T Hashihayata, N Ohtake… - Bioorganic & medicinal …, 2003 - Elsevier
The identification of potent and selective orexin-2 receptor (OX 2 R) antagonists is described
based on the modification of N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline analogue …

Structure–activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists

…, K Ohwaki, T Saeki, K Noguchi, N Ohtake - Bioorganic & medicinal …, 2003 - Elsevier
The structure–activity relationships of xanthene carboxamide derivatives on the CCR1
receptor binding affinity and the functional antagonist activity were described. Previously, we …

Lead identification of 8-(methylamino)-2-oxo-1, 2-dihydroquinoline derivatives as DNA gyrase inhibitors: hit-to-lead generation involving thermodynamic evaluation

…, K Hitaka, K Iwamoto, H Sugiyama, N Ohtake - ACS …, 2020 - ACS Publications
DNA gyrase and topoisomerase IV are well-validated pharmacological targets, and quinolone
antibacterial drugs are marketed as their representative inhibitors. However, in recent …

Dicationic dithiocarbamate carbapenems with anti-MRSA activity

H Imamura, N Ohtake, H Jona, A Shimizu… - Bioorganic & medicinal …, 2001 - Elsevier
A new class of 1β-methylcarbapenems bearing a doubly quaternarized 1,4-diazabicyclooctane
(DABCO) substituted dithiocarbamate moiety at the C-2 side chain was prepared, and …

Design, synthesis, and discovery of a novel CCR1 antagonist

…, Y Iwasawa, K Noguchi, N Ohtake - Journal of medicinal …, 2001 - ACS Publications
The CC chemokines may play an important role in the pathogenesis of chronic inflammatory
diseases including rheumatoid arthritis, and their effects are thought to be mediated through …

Discovery and structure–activity relationships of a novel class of quinazoline glucokinase activators

…, S Ohyama, K Sasaki, M Chiba, N Ohtake… - Bioorganic & medicinal …, 2009 - Elsevier
We describe design, syntheses and structure–activity relationships of a novel class of 4,6-disubstituted
quinazoline glucokinase activators. Prototype quinazoline leads (4 and 5) were …

Fragment-based discovery of novel non-hydroxamate LpxC inhibitors with antibacterial activity

…, R Kurimoto-Tsuruta, Y Ogata, N Ohtake… - Journal of Medicinal …, 2020 - ACS Publications
UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) is a zinc metalloenzyme that catalyzes
the first committed step in the biosynthesis of Lipid A, an essential component of the cell …

Discovery of a novel CCR3 selective antagonist

…, K Ohwaki, T Saeki, K Noguchi, N Ohtake - Bioorganic & medicinal …, 2001 - Elsevier
In searching for a novel CCR3 receptor antagonist, we designed a library that included a
variety of carboxamide derivatives based on the structure of our potent antagonists for human …

Design, syntheses, and structure–activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro [isobenzofuran-1 (3H), 4′-piperidin]-1′-yl} …

Y Ogino, N Ohtake, Y Nagae, K Matsuda… - Bioorganic & medicinal …, 2008 - Elsevier
Design, syntheses, and structure–activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole
NPY Y5 receptor antagonists are …

A Potent, Long-Acting, Orally Active (2 R)-2-[(1 R)-3, 3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: A Novel Muscarinic M3 Receptor Antagonist with High …

…, A Satoh, Y Ogino, T Kakikawa, N Ohtake… - Journal of medicinal …, 2000 - ACS Publications
A novel series of (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamides was
designed and synthesized based on the structure and biological profiles of an active …